Skip to Main Content

Paper Details

Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.
Cancer Res
47
2018
AR, Androgen, Primary prostate cancer, Prostate, Prostate Tumor, RB1, abiraterone acetate, aggressive subclones, androgen, androgen receptor, leuprolide, mCRPC, men, metastatic castration-resistant prostate cancer, oncogenic, prednisone, primary prostate cancer, prostate cancer, subclones, tumor, tumors
Author NameAffiliation
Adam G SowalskyBeth Israel Deaconess Medical Center
Adam G SowalskyNational Cancer Institute
Huihui YeBeth Israel Deaconess Medical Center
Eliezer M Van AllenLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Eliezer M Van AllenLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Massimo LodaBrigham and Women's Hospital
Massimo LodaDana Farber Cancer Institute
Rosina T LisLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Bruce MontgomeryUniversity of Washington
Elahe A MostaghelUniversity of Washington
Peter S NelsonUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Research Center
Mary-Ellen TaplinLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Steven P BalkBeth Israel Deaconess Medical Center
  • 1 - 16

Datasets

Release 1.2